Related Experiment Videos
How well are the cardiovascular risk profiles modulated by current beta blockers in hypertension?
1Marien-Hospital, Düsseldorf, FRG.
Insights
Antihypertensive drugs effectively reduce stroke risk but show limited benefit for coronary events. Further research is needed to understand this cardiovascular protection difference and the role of beta-blockers.
Area of Science:
- Cardiology
- Pharmacology
- Epidemiology
Background:
- Antihypertensive treatments significantly reduce cerebrovascular events (42%) and cardiac events (24%) per major clinical trials.
- However, observed coronary event reduction is only 14%, indicating a dichotomy in cardiovascular protection.
- The precise reasons for this disparity in antihypertensive drug efficacy remain unclear.
Purpose of the Study:
- To investigate the reasons behind the differential cardiovascular protection offered by antihypertensive drugs.
- To explore the potential role of beta-adrenoceptor antagonists in cardiovascular protection.
- To examine the hypothesis that metabolic effects of beta-blockers may influence their cardiac benefits.
Main Methods:
- Review of epidemiologic studies and clinical trial data on antihypertensive treatment.
- Comparative analysis of cardiovascular outcomes associated with different classes of antihypertensive drugs.
- Evaluation of the pharmacodynamic and metabolic properties of beta-adrenoceptor antagonists.
Main Results:
- Antihypertensive therapy effectively reduces cerebrovascular events as predicted.
- Coronary event reduction is significantly lower than predicted, highlighting a gap in cardiovascular protection.
- Beta-adrenoceptor antagonists have not demonstrated superior outcomes compared to other antihypertensives despite theoretical cardiac benefits.
Conclusions:
- There is a significant discrepancy between the predicted and observed reduction in coronary events with antihypertensive treatment.
- The potential cardiac benefits of beta-adrenoceptor antagonists may be counteracted by adverse metabolic effects.
- Further clinical trials are necessary to test the hypothesis that newer beta-blockers with favorable metabolic profiles offer enhanced cardiac protection.
Abstract:
Epidemiologic studies predict that reduction of the systemic blood pressure by the amount usually achieved in major clinical trials could be expected to reduce cerebrovascular events by 42% and cardiac events by 24%. Although antihypertensive treatment achieves the expected cerebrovascular benefits, the risk of coronary events is reduced by only 14%. The reason for this dichotomy in cardiovascular protection afforded by antihypertensive drugs is unknown. Compared to treatment with other antihypertensive drugs, treatment with beta-adrenoceptor antagonists has not yielded a superior outcome despite the fact that they possess some cardiac pharmacodynamic properties that could be potentially advantageous in the prevention of coronary heart disease. It is an untested argument that conventional beta-adrenoceptor antagonists possess unwanted metabolic effects that may counter some of their potential cardiac benefits. Newer drugs of this group possess ancillary metabolic characteristics which may convey more cardiac protection, but in the absence of results of formal clinical trials this hypothesis remains to be tested.